INDICATIONS
- Ischemic heart disease
- Viability assessment prior to revascularization
- Acute and chronic MI – location and extent of infarct including transmurality, area at risk, microvascular obstruction (areas of no-reflow), complications such as aneurysms and thrombus formation
- Heart Failure
- Differentiate between ischemic and nonischemic cardiomyopathy
- Assessment of LV/RV size and function with precise quantification
- Cardiomyopathies
- Evaluation of dilated CM in setting of normal coronaries
- HCM – risk stratification with extent of hypertrophy, myocardial fibrosis, and quantification of sub-aortic gradient
- Infiltrative diseases – sarcoid, amyloid, hemochromatosis T2* iron quantification
- Myocarditis
- ARVC
- Noncompaction
- Cardiac masses and thrombi
- Pericardial disease
- Valvular disease
- Detection, quantification, serial effect on LV performance – peak velocity, gradient, planimetry, regurgitant fractions
- Valve masses
- Congenital heart disease
- Coronary artery origin evaluation for anomalies